Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good evening MICK
Grab more today
Huge dump is coming. Tax write-off coming so dump this scam before it get below $1 soon
Thanks for sharing my Friend
Just got into Texas
$MULN BOLLINGER MOTORS ANNOUNCES OUR NEXT ENERGY AS BATTERY SUPPLIER FOR ELECTRIC COMMERCIAL TRUCKS
Source: GlobeNewswire Inc.
via InvestorWire -- Bollinger Motors, which recently became a majority owned company of Mullen Automotive, Inc. (NASDAQ: MULN), has announced Our Next Energy will be supplying modular, linkable Aries battery packs to power its all-electric commercial platforms and chassis cabs.
“ONE battery packs are ideal for our commercial trucks, giving our customers the range they need,” said Robert Bollinger, founder and CEO of Bollinger Motors. “The fact they’ll be built in the US and in Michigan is a huge advantage for us going forward.”
Bollinger's all-electric Class 4 through Class 6 chassis cabs are designed to meet commercial customers’ needs in a segment that often requires large payloads, sufficient range, durability, and longevity.
“We are pleased to provide Bollinger commercial vehicles with industry-leading range, using our Aries LFP battery platform,” said Mujeeb Ijaz, founder and CEO of ONE. “The Aries LFP chemistry contains no nickel and cobalt, offering superior durability and daily charging up to 100% without compromise."
"Halting development of our batteries in-house and teaming up with O.N.E. is a win-win in both technological advancement and production logistics," says Bryan Chambers, COO of Bollinger Motors. "We've not only advanced the quality of our product, but moved our fleet delivery dates closer."
Bollinger Motors will first launch their Class 4 Chassis Cab which is designed to hold 1 or 2 battery packs, depending on the customer’s desired range needs. Class 5 Platforms for walk-in van upfits will follow. The packs are expected to be available for Bollinger’s anticipated start of production in late 2023.
###
ABOUT BOLLINGER MOTORS
Founded in 2015 by Robert Bollinger, Bollinger Motors is a U.S.-based company, headquartered in Oak Park, Michigan. Bollinger Motors will manufacture all-electric platforms and chassis cabs for commercial vehicles in Classes 4-6. www.BollingerMotors.com
PRESS CONTACT
BOLLINGER MOTORS
Valentine Oldham
Principal, Valentine PR
valentine@valentinepr.com
617 721 5392
ABOUT OUR NEXT ENERGY
Our Next Energy, Inc. (ONE) is a Michigan-based energy storage company focused on battery technologies that will radically accelerate the adoption of electric vehicles and expand the possibilities of next-level storage solutions. Our vision is simple: Double the range of electric vehicles; use safer, more sustainable raw materials; and establish a localized supply chain. This strategy will result in a reliable, cost-effective, and conflict-free supply chain.
www.one.ai
PRESS CONTACT
OUR NEXT ENERGY
Sydni Williams
Communications Manager
swilliams@one.ai
734 272 2910
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "continue," "will," "may," "could," "should," "expect," "expected," "plans," "intend," "anticipate," "believe," "estimate," "predict," "potential" and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Bollinger Motors and are difficult to predict. Examples of such risks and uncertainties include: (a) Bollinger Motors’ receipt of initial orders for the product by the anticipated availability date; (b) ONE’s ability to produce and deliver the product at anticipated production volume demands; (c) ONE’s ability to deliver a battery product with the expected range; (d) ONE’s ability to deliver the product at the anticipated cost; or (d) Bollinger Motors’ future business decisions related to in-house battery development. Additional examples of such risks and uncertainties include but are not limited to: (i) Bollinger Motors’ ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Bollinger Motors’ ability to maintain existing, and secure additional, contracts with manufacturers, parts and other service providers relating to its business; (iii) Bollinger Motors’ ability to successfully expand in existing markets and enter new markets; (iv) Bollinger Motors’ ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Bollinger Motors’ business; (viii) changes in government licensing and regulation that may adversely affect Bollinger Motors’ business; (ix) the risk that changes in consumer behavior could adversely affect Bollinger Motors’ business; (x) Bollinger Motors’ ability to protect its intellectual property; (xi) the vehicles developed will perform as expected and (xii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Mullen Automotive, Inc., of which Bollinger Motors is a partially-owned subsidiary, with the Securities and Exchange Commission. Bollinger Motors anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Bollinger Motors assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Bollinger Motors’ plans and expectations as of any subsequent date.
Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com
Primary Logo
$MULN BOLLINGER MOTORS ANNOUNCES OUR NEXT ENERGY AS BATTERY SUPPLIER FOR ELECTRIC COMMERCIAL TRUCKS
Source: GlobeNewswire Inc.
via InvestorWire -- Bollinger Motors, which recently became a majority owned company of Mullen Automotive, Inc. (NASDAQ: MULN), has announced Our Next Energy will be supplying modular, linkable Aries battery packs to power its all-electric commercial platforms and chassis cabs.
“ONE battery packs are ideal for our commercial trucks, giving our customers the range they need,” said Robert Bollinger, founder and CEO of Bollinger Motors. “The fact they’ll be built in the US and in Michigan is a huge advantage for us going forward.”
Bollinger's all-electric Class 4 through Class 6 chassis cabs are designed to meet commercial customers’ needs in a segment that often requires large payloads, sufficient range, durability, and longevity.
“We are pleased to provide Bollinger commercial vehicles with industry-leading range, using our Aries LFP battery platform,” said Mujeeb Ijaz, founder and CEO of ONE. “The Aries LFP chemistry contains no nickel and cobalt, offering superior durability and daily charging up to 100% without compromise."
"Halting development of our batteries in-house and teaming up with O.N.E. is a win-win in both technological advancement and production logistics," says Bryan Chambers, COO of Bollinger Motors. "We've not only advanced the quality of our product, but moved our fleet delivery dates closer."
Bollinger Motors will first launch their Class 4 Chassis Cab which is designed to hold 1 or 2 battery packs, depending on the customer’s desired range needs. Class 5 Platforms for walk-in van upfits will follow. The packs are expected to be available for Bollinger’s anticipated start of production in late 2023.
###
ABOUT BOLLINGER MOTORS
Founded in 2015 by Robert Bollinger, Bollinger Motors is a U.S.-based company, headquartered in Oak Park, Michigan. Bollinger Motors will manufacture all-electric platforms and chassis cabs for commercial vehicles in Classes 4-6. www.BollingerMotors.com
PRESS CONTACT
BOLLINGER MOTORS
Valentine Oldham
Principal, Valentine PR
valentine@valentinepr.com
617 721 5392
ABOUT OUR NEXT ENERGY
Our Next Energy, Inc. (ONE) is a Michigan-based energy storage company focused on battery technologies that will radically accelerate the adoption of electric vehicles and expand the possibilities of next-level storage solutions. Our vision is simple: Double the range of electric vehicles; use safer, more sustainable raw materials; and establish a localized supply chain. This strategy will result in a reliable, cost-effective, and conflict-free supply chain.
www.one.ai
PRESS CONTACT
OUR NEXT ENERGY
Sydni Williams
Communications Manager
swilliams@one.ai
734 272 2910
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "continue," "will," "may," "could," "should," "expect," "expected," "plans," "intend," "anticipate," "believe," "estimate," "predict," "potential" and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Bollinger Motors and are difficult to predict. Examples of such risks and uncertainties include: (a) Bollinger Motors’ receipt of initial orders for the product by the anticipated availability date; (b) ONE’s ability to produce and deliver the product at anticipated production volume demands; (c) ONE’s ability to deliver a battery product with the expected range; (d) ONE’s ability to deliver the product at the anticipated cost; or (d) Bollinger Motors’ future business decisions related to in-house battery development. Additional examples of such risks and uncertainties include but are not limited to: (i) Bollinger Motors’ ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Bollinger Motors’ ability to maintain existing, and secure additional, contracts with manufacturers, parts and other service providers relating to its business; (iii) Bollinger Motors’ ability to successfully expand in existing markets and enter new markets; (iv) Bollinger Motors’ ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Bollinger Motors’ business; (viii) changes in government licensing and regulation that may adversely affect Bollinger Motors’ business; (ix) the risk that changes in consumer behavior could adversely affect Bollinger Motors’ business; (x) Bollinger Motors’ ability to protect its intellectual property; (xi) the vehicles developed will perform as expected and (xii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Mullen Automotive, Inc., of which Bollinger Motors is a partially-owned subsidiary, with the Securities and Exchange Commission. Bollinger Motors anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Bollinger Motors assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Bollinger Motors’ plans and expectations as of any subsequent date.
Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com
Primary Logo
I am in Florida and heading to Texas tomorrow
I love the short squeeze
I think so
I think so….bottom play I hope
I am in MULN
Thank you
Awesome news….it is a best time of the year to buy this one and hold for long
Go $MULN
Short squeeze is coming
Thanks for sharing
$MULN Mullen Enters Into Agreement With Newgate Motor Group, One of Ireland's Most Recognized Auto Groups, to Distribute Mullen I-GO™ in Ireland and United Kingdom
Source: InvestorsHub NewsWire
Dealer Group Agrees to Purchase 500 Vehicles per Year
Agreement appoints Newgate as marketing, sales, distribution and servicing agent for the Mullen I-GO in Ireland and the UK.
Newgate will purchase initial units of the I-GO for vehicle demonstrations, marketing and sales opportunities with potential customers.
Expected delivery date for the Mullen I-GO samples is Dec. 20, 2022.
Brea, CA -- November 9, 2022 -- InvestorsHub NewsWire -- Mullen Automotive, Inc. (NASDAQ:MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that it has entered into an agreement to appoint Newgate Motor Group, one of Ireland’s most recognized dealership groups, as the marketing, sales, distribution and servicing agent for the Mullen I-GO in Ireland and the United Kingdom.
Newgate Motor Group has over 40 years of experience in the motor industry and has built an excellent reputation during that time. They are well respected in the auto industry and represent several brands, including Renault/Dacia, Kia and Mercedes-Benz. In addition to being a key retail group in Ireland, they also have substantial relationships in the vehicle distribution business throughout the United Kingdom and various parts of Europe. Newgate Motor Group also represents XBUS and Evetta electric vehicles from the German-based company Electric Brands.
The I-GO is Mullen’s recently announced urban commercial delivery vehicle, designed to bridge the gap between the growing demand for quick deliveries and space constraints in dense cities throughout Europe. The Mullen I-GO is EU standard homologated, certified and ready for sale in initial markets of the U.K., Germany, Spain, France and Ireland, with the first vehicles set to be released in Germany in December 2022.
Mullen and Newgate will also enter into a dealer agreement, which will encompass sales training, service training, flooring, parts, warranty and similar matters that an OEM would typically provide to its dealers. That agreement will also address the terms upon which Newgate Motor Group will purchase the initial units of the I-GO for vehicle demonstrations and the 500-vehicles-per-year purchase order. The expected delivery date for the first shipment of vehicles is Dec. 20, 2022.
“This is a highly strategic partnership for Mullen, with Newgate being one of Ireland’s most recognizable dealers for new and used vehicles; it brings us an incredible opportunity to enter the commercial EV market in Europe with a very successful retail group,” said David Michery, CEO and chairman of Mullen Automotive. “We are currently working closely with Newgate on the importation, registration and licensing requirements for the successful import and distribution of the I-GO into Ireland and the United Kingdom.”
“We believe the Mullen I-GO is the logistical solution the European market is looking for as demand increases for zero-emission delivery vehicles. The demand for zero-emission, compact delivery vehicles has never been higher, and we believe Mullen has produced a vehicle to meet this demand and has the potential to command a substantial market share,” said James Ring, general manager of Newgate Motor Group.
The I-GO will join Mullen’s current commercial vehicle lineup, which includes Class 1 and 2 EV cargo vans. Mullen recently made a majority acquisition of Bollinger Motors, whose portfolio includes Class 3 through Class 6 commercial vehicles. In addition to securing the exclusive sales, distribution and branding rights for the I-GO for Spain, France, Germany, the U.K. and Ireland, the Company entered into an asset purchase agreement to acquire all assets of Electric Last Mile Solutions, Inc. and Electric Last Mile, Inc. (“ELMS”) from the ELMS Bankruptcy Estates.
About Mullen
Mullen Automotive is a Southern California-based automotive company building the next generation of premium electric vehicles (EVs) that are affordable and built entirely in the United States. With an end-to-end ecosystem that supports owners from test driving to financing and servicing through a unique hybrid dealership model, customers are supported through every aspect of EV ownership. The Mullen FIVE, the Company’s first electric crossover, is slated for delivery in 2024 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. To learn more about the Company, visit www.MullenUSA.com.
About Newgate Motor Group
Newgate Motor Group is an Irish family-owned business and one of Ireland’s most recognized vehicle retailers. Newgate currently represents several brands, including Renault passenger cars and commercial vehicles, Dacia, Kia and Mercedes-Benz. Newgate offers the highest level of service and expertise, whether customers wish to maintain current vehicles or are looking to upgrade to a new or used car. We stock the latest models and a wide variety of used cars, from small to luxury premium vehicles. We are also authorized to facilitate your vehicle finance requirements, and we stock the full range of Mercedes-Benz, Renault, Dacia and Kia genuine parts. Newgate Motor Group boasts a state-of-the-art facility in Navan, with workshops equipped to service and maintain Renault, Dacia, Kia and Mercedes vehicles.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "continue," "will," "may," "could," "should," "expect," "expected," "plans," "intend," "anticipate," "believe," "estimate," "predict," "potential" and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to: whether Mullen and Newgate Motor Group will agree on terms of the dealer agreement, including but not limited to the terms of the 500-vehicles-per-year purchase order; whether the Sample I-GOs will be delivered to Newgate within the expected time frame; whether the agreement and relationship with Newgate Motors Group will be a success; and whether the I-GO will be a success in the European or other markets. Additional examples of such risks and uncertainties include but are not limited to: (i) Mullen’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Mullen's ability to maintain existing, and secure additional, contracts with manufacturers, parts and other service providers relating to its business; (iii) Mullen’s ability to successfully expand in existing markets and enter new markets; (iv) Mullen’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Mullen’s business; (viii) changes in government licensing and regulation that may adversely affect Mullen’s business; (ix) the risk that changes in consumer behavior could adversely affect Mullen’s business; (x) Mullen’s ability to protect its intellectual property; and (xi) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.
Contact:
Mullen Automotive, Inc.
+1 (714) 613-1900
www.MullenUSA.com
$MULN Mullen Enters Into Agreement With Newgate Motor Group, One of Ireland's Most Recognized Auto Groups, to Distribute Mullen I-GO™ in Ireland and United Kingdom
Source: InvestorsHub NewsWire
Dealer Group Agrees to Purchase 500 Vehicles per Year
Agreement appoints Newgate as marketing, sales, distribution and servicing agent for the Mullen I-GO in Ireland and the UK.
Newgate will purchase initial units of the I-GO for vehicle demonstrations, marketing and sales opportunities with potential customers.
Expected delivery date for the Mullen I-GO samples is Dec. 20, 2022.
Brea, CA -- November 9, 2022 -- InvestorsHub NewsWire -- Mullen Automotive, Inc. (NASDAQ:MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that it has entered into an agreement to appoint Newgate Motor Group, one of Ireland’s most recognized dealership groups, as the marketing, sales, distribution and servicing agent for the Mullen I-GO in Ireland and the United Kingdom.
Newgate Motor Group has over 40 years of experience in the motor industry and has built an excellent reputation during that time. They are well respected in the auto industry and represent several brands, including Renault/Dacia, Kia and Mercedes-Benz. In addition to being a key retail group in Ireland, they also have substantial relationships in the vehicle distribution business throughout the United Kingdom and various parts of Europe. Newgate Motor Group also represents XBUS and Evetta electric vehicles from the German-based company Electric Brands.
The I-GO is Mullen’s recently announced urban commercial delivery vehicle, designed to bridge the gap between the growing demand for quick deliveries and space constraints in dense cities throughout Europe. The Mullen I-GO is EU standard homologated, certified and ready for sale in initial markets of the U.K., Germany, Spain, France and Ireland, with the first vehicles set to be released in Germany in December 2022.
Mullen and Newgate will also enter into a dealer agreement, which will encompass sales training, service training, flooring, parts, warranty and similar matters that an OEM would typically provide to its dealers. That agreement will also address the terms upon which Newgate Motor Group will purchase the initial units of the I-GO for vehicle demonstrations and the 500-vehicles-per-year purchase order. The expected delivery date for the first shipment of vehicles is Dec. 20, 2022.
“This is a highly strategic partnership for Mullen, with Newgate being one of Ireland’s most recognizable dealers for new and used vehicles; it brings us an incredible opportunity to enter the commercial EV market in Europe with a very successful retail group,” said David Michery, CEO and chairman of Mullen Automotive. “We are currently working closely with Newgate on the importation, registration and licensing requirements for the successful import and distribution of the I-GO into Ireland and the United Kingdom.”
“We believe the Mullen I-GO is the logistical solution the European market is looking for as demand increases for zero-emission delivery vehicles. The demand for zero-emission, compact delivery vehicles has never been higher, and we believe Mullen has produced a vehicle to meet this demand and has the potential to command a substantial market share,” said James Ring, general manager of Newgate Motor Group.
The I-GO will join Mullen’s current commercial vehicle lineup, which includes Class 1 and 2 EV cargo vans. Mullen recently made a majority acquisition of Bollinger Motors, whose portfolio includes Class 3 through Class 6 commercial vehicles. In addition to securing the exclusive sales, distribution and branding rights for the I-GO for Spain, France, Germany, the U.K. and Ireland, the Company entered into an asset purchase agreement to acquire all assets of Electric Last Mile Solutions, Inc. and Electric Last Mile, Inc. (“ELMS”) from the ELMS Bankruptcy Estates.
About Mullen
Mullen Automotive is a Southern California-based automotive company building the next generation of premium electric vehicles (EVs) that are affordable and built entirely in the United States. With an end-to-end ecosystem that supports owners from test driving to financing and servicing through a unique hybrid dealership model, customers are supported through every aspect of EV ownership. The Mullen FIVE, the Company’s first electric crossover, is slated for delivery in 2024 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. To learn more about the Company, visit www.MullenUSA.com.
About Newgate Motor Group
Newgate Motor Group is an Irish family-owned business and one of Ireland’s most recognized vehicle retailers. Newgate currently represents several brands, including Renault passenger cars and commercial vehicles, Dacia, Kia and Mercedes-Benz. Newgate offers the highest level of service and expertise, whether customers wish to maintain current vehicles or are looking to upgrade to a new or used car. We stock the latest models and a wide variety of used cars, from small to luxury premium vehicles. We are also authorized to facilitate your vehicle finance requirements, and we stock the full range of Mercedes-Benz, Renault, Dacia and Kia genuine parts. Newgate Motor Group boasts a state-of-the-art facility in Navan, with workshops equipped to service and maintain Renault, Dacia, Kia and Mercedes vehicles.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "continue," "will," "may," "could," "should," "expect," "expected," "plans," "intend," "anticipate," "believe," "estimate," "predict," "potential" and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to: whether Mullen and Newgate Motor Group will agree on terms of the dealer agreement, including but not limited to the terms of the 500-vehicles-per-year purchase order; whether the Sample I-GOs will be delivered to Newgate within the expected time frame; whether the agreement and relationship with Newgate Motors Group will be a success; and whether the I-GO will be a success in the European or other markets. Additional examples of such risks and uncertainties include but are not limited to: (i) Mullen’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Mullen's ability to maintain existing, and secure additional, contracts with manufacturers, parts and other service providers relating to its business; (iii) Mullen’s ability to successfully expand in existing markets and enter new markets; (iv) Mullen’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Mullen’s business; (viii) changes in government licensing and regulation that may adversely affect Mullen’s business; (ix) the risk that changes in consumer behavior could adversely affect Mullen’s business; (x) Mullen’s ability to protect its intellectual property; and (xi) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.
Contact:
Mullen Automotive, Inc.
+1 (714) 613-1900
www.MullenUSA.com
$ECOR electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers
Source: PR Newswire (US)
ROCKAWAY, N.J. and CHARLOTTE, N.C., Nov. 1, 2022 /PRNewswire/ -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage, bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA cleared non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within select managed care health systems.
"Joerns' mission is to simplify care delivery so providers can focus on patients' needs and payors can be confident that the best value-based therapies are available to their beneficiaries," said Doug Ferguson, Chief Strategy Officer at Joerns Healthcare. "Assisting in the distribution and billing of electroCore's Sapphire nVNS therapy will make it easier for managed care and other providers to ensure their patients have access to optimal therapies when and where they need them."
"We are excited to be working with Joerns as we expand patient access to our therapy," commented Dan Goldberger, Chief Executive Officer of electroCore. "Joerns is a trusted partner of many large managed care companies, and this partnership enables us to expand the use of gammaCore nVNS technology for sufferers of primary headache within a self-insured managed care organization, reinforcing the company's strategy of providing patients with greater access and ease to our nVNS therapy."
About Joerns Healthcare, LLC
Joerns Healthcare is a healthcare technology and equipment services company focused on driving the transformation of care nationally across the post-acute continuum. We are simplifying the complex post-acute care world by providing the technology, professionals, products, and data to help streamline the process, so providers concentrate on care. Joerns brings our national service footprint, the right products, and over 130 years of expertise to help navigate the new complexities that surround accountable care and optimize patient and financial outcomes.
For more information, visit Joerns.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
Safety and efficacy of gammaCore have not been evaluated in the following patients:
Adolescent patients with congenital cardiac issues
Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
Pediatric patients (less than 12 years)
Pregnant women
Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
For more information, please visit gammaCore.com
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company's business prospects through Joerns, Kaiser and other self-insured managed care organizations or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore's results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Media Contacts:
Joerns Healthcare
Lindy Plummer
lindy.plummer@joerns.com
CG Capital
Rich Cockrell
404-736-3838
ecor@cg.capital
Cision View original content:https://www.prnewswire.com/news-releases/electrocore-and-joerns-healthcare-partner-to-expand-use-of-gammacore-vagus-nerve-technology-for-headache-sufferers-301665135.html
SOURCE Joerns Healthcare
Copyright 2022 PR Newswire
$ECOR electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers
Source: PR Newswire (US)
ROCKAWAY, N.J. and CHARLOTTE, N.C., Nov. 1, 2022 /PRNewswire/ -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage, bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA cleared non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within select managed care health systems.
"Joerns' mission is to simplify care delivery so providers can focus on patients' needs and payors can be confident that the best value-based therapies are available to their beneficiaries," said Doug Ferguson, Chief Strategy Officer at Joerns Healthcare. "Assisting in the distribution and billing of electroCore's Sapphire nVNS therapy will make it easier for managed care and other providers to ensure their patients have access to optimal therapies when and where they need them."
"We are excited to be working with Joerns as we expand patient access to our therapy," commented Dan Goldberger, Chief Executive Officer of electroCore. "Joerns is a trusted partner of many large managed care companies, and this partnership enables us to expand the use of gammaCore nVNS technology for sufferers of primary headache within a self-insured managed care organization, reinforcing the company's strategy of providing patients with greater access and ease to our nVNS therapy."
About Joerns Healthcare, LLC
Joerns Healthcare is a healthcare technology and equipment services company focused on driving the transformation of care nationally across the post-acute continuum. We are simplifying the complex post-acute care world by providing the technology, professionals, products, and data to help streamline the process, so providers concentrate on care. Joerns brings our national service footprint, the right products, and over 130 years of expertise to help navigate the new complexities that surround accountable care and optimize patient and financial outcomes.
For more information, visit Joerns.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
Safety and efficacy of gammaCore have not been evaluated in the following patients:
Adolescent patients with congenital cardiac issues
Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
Pediatric patients (less than 12 years)
Pregnant women
Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
For more information, please visit gammaCore.com
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company's business prospects through Joerns, Kaiser and other self-insured managed care organizations or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore's results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Media Contacts:
Joerns Healthcare
Lindy Plummer
lindy.plummer@joerns.com
CG Capital
Rich Cockrell
404-736-3838
ecor@cg.capital
Cision View original content:https://www.prnewswire.com/news-releases/electrocore-and-joerns-healthcare-partner-to-expand-use-of-gammacore-vagus-nerve-technology-for-headache-sufferers-301665135.html
SOURCE Joerns Healthcare
Copyright 2022 PR Newswire
$WSRC Western Sierra Announces FINAL Contract for $1.5 Billion Federally Funded Project Through the Company's Wholly Owned Subsidiary
https://www.marketwatch.com/press-release/western-sierra-announces-final-contract-for-15-billion-federally-funded-project-through-the-companys-wholly-owned-subsidiary-2022-10-25?mod=mw_quote_news_seemore
$MLRT $.3997
$INKW $.0061
$NEWYY $.0542
$SNPW $.0089
$CGRA $.0424
$TPRFF $2.05
Thanks for sharing
I am little busy lately but will try to be back
$ECOR electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers
Source: PR Newswire (US)
ROCKAWAY, N.J. and CHARLOTTE, N.C., Nov. 1, 2022 /PRNewswire/ -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage, bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA cleared non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within select managed care health systems.
"Joerns' mission is to simplify care delivery so providers can focus on patients' needs and payors can be confident that the best value-based therapies are available to their beneficiaries," said Doug Ferguson, Chief Strategy Officer at Joerns Healthcare. "Assisting in the distribution and billing of electroCore's Sapphire nVNS therapy will make it easier for managed care and other providers to ensure their patients have access to optimal therapies when and where they need them."
"We are excited to be working with Joerns as we expand patient access to our therapy," commented Dan Goldberger, Chief Executive Officer of electroCore. "Joerns is a trusted partner of many large managed care companies, and this partnership enables us to expand the use of gammaCore nVNS technology for sufferers of primary headache within a self-insured managed care organization, reinforcing the company's strategy of providing patients with greater access and ease to our nVNS therapy."
About Joerns Healthcare, LLC
Joerns Healthcare is a healthcare technology and equipment services company focused on driving the transformation of care nationally across the post-acute continuum. We are simplifying the complex post-acute care world by providing the technology, professionals, products, and data to help streamline the process, so providers concentrate on care. Joerns brings our national service footprint, the right products, and over 130 years of expertise to help navigate the new complexities that surround accountable care and optimize patient and financial outcomes.
For more information, visit Joerns.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
Safety and efficacy of gammaCore have not been evaluated in the following patients:
Adolescent patients with congenital cardiac issues
Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
Pediatric patients (less than 12 years)
Pregnant women
Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
For more information, please visit gammaCore.com
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company's business prospects through Joerns, Kaiser and other self-insured managed care organizations or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore's results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Media Contacts:
Joerns Healthcare
Lindy Plummer
lindy.plummer@joerns.com
CG Capital
Rich Cockrell
404-736-3838
ecor@cg.capital
Cision View original content:https://www.prnewswire.com/news-releases/electrocore-and-joerns-healthcare-partner-to-expand-use-of-gammacore-vagus-nerve-technology-for-headache-sufferers-301665135.html
SOURCE Joerns Healthcare
Copyright 2022 PR Newswire
$ECOR electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers
Source: PR Newswire (US)
ROCKAWAY, N.J. and CHARLOTTE, N.C., Nov. 1, 2022 /PRNewswire/ -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage, bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA cleared non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within select managed care health systems.
"Joerns' mission is to simplify care delivery so providers can focus on patients' needs and payors can be confident that the best value-based therapies are available to their beneficiaries," said Doug Ferguson, Chief Strategy Officer at Joerns Healthcare. "Assisting in the distribution and billing of electroCore's Sapphire nVNS therapy will make it easier for managed care and other providers to ensure their patients have access to optimal therapies when and where they need them."
"We are excited to be working with Joerns as we expand patient access to our therapy," commented Dan Goldberger, Chief Executive Officer of electroCore. "Joerns is a trusted partner of many large managed care companies, and this partnership enables us to expand the use of gammaCore nVNS technology for sufferers of primary headache within a self-insured managed care organization, reinforcing the company's strategy of providing patients with greater access and ease to our nVNS therapy."
About Joerns Healthcare, LLC
Joerns Healthcare is a healthcare technology and equipment services company focused on driving the transformation of care nationally across the post-acute continuum. We are simplifying the complex post-acute care world by providing the technology, professionals, products, and data to help streamline the process, so providers concentrate on care. Joerns brings our national service footprint, the right products, and over 130 years of expertise to help navigate the new complexities that surround accountable care and optimize patient and financial outcomes.
For more information, visit Joerns.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
Safety and efficacy of gammaCore have not been evaluated in the following patients:
Adolescent patients with congenital cardiac issues
Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
Pediatric patients (less than 12 years)
Pregnant women
Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
For more information, please visit gammaCore.com
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company's business prospects through Joerns, Kaiser and other self-insured managed care organizations or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore's results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Media Contacts:
Joerns Healthcare
Lindy Plummer
lindy.plummer@joerns.com
CG Capital
Rich Cockrell
404-736-3838
ecor@cg.capital
Cision View original content:https://www.prnewswire.com/news-releases/electrocore-and-joerns-healthcare-partner-to-expand-use-of-gammacore-vagus-nerve-technology-for-headache-sufferers-301665135.html
SOURCE Joerns Healthcare
Copyright 2022 PR Newswire
I bought at $2 and dump at $2.8
Love the tech